Capital Rx Drug Recall Report

SEPTEMBER 2024

Capital Rx

Welcome to the Capital Rx Drug Recall Report. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **9/25/2024****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
8/28/2024	Class 2	Testosterone Gel 1.62%	Teva Pharmaceuticals USA, Inc	00591-2925-30, 00591-2925-32	100042386, EXP 06/1/2025	The product being super potent (too strong).
8/28/2024	Class 2	Timolol Maleate 0.5% Solution	FDC Limited	64980-0514-05, 64980-0514-01	083K063, EXP 10/31/2025; 083I091, EXP 08/31/2025	A defective container. There was a spike from the cap blocking the opening of the container nozzle.
9/4/2024	Class 1	Freestyle Libre 3 Sensor	Abbott Diabetes Care, Inc.	57599-0818-00	T60001948, T60001966, T60001969	A small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings, which if undetected may pose a potential health risk for people living with diabetes.

Capital Rx Drug Recall Report

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
9/4/2024	Class 2	Cefixime Suspension 100 Mg/5ml	Lupin Pharmaceuticals Inc.	68180-0405-01	F201517, EXP 11/30/2024	The product being subpotent (not strong enough).
9/4/2024	Class 2	Ibuprofen 400 Mg Tablets	Dr. Reddy's Laboratories, Inc.	55111-0682-01, 55111-0682-05	A) C2207529, EXP 5/31/2026; C2210993, EXP 9/30/2026. B) C2207530, EXP 5/31/2026; C2210992, C2210994, EXP 9/30/2026; C2213304, C2213305, EXP 11/30/2026	Failing to meet impurity and degradation standards.
9/4/2024	Class 2	Ibuprofen 600 Mg Tablets	Dr. Reddy's Laboratories, Inc.	55111-0683-01, 05511-0683-05	A) C2207527, EXP 5/31/2026; C2210864, EXP 9/30/2026; C2213018, EXP 11/30/2026. B) C2207528, EXP 5/31/2026; C2210860, EXP 9/30/2026; C2213016, C2213017, EXP 11/30/2026; C2301852, C2302056, C2302057, EXP 1/31/2027	Failing to meet impurity and degradation standards.
9/4/2024	Class 2	Ibuprofen 800 Mg Tablets	Dr. Reddy's Laboratories, Inc.	55111-0684-01, 55111-0684-05	A) C2207525, EXP 5/31/2026; C2212902, EXP 11/30/2026. B) C2207526, EXP 5/31/2026; C2210751, C2210752, EXP 9/30/2026; C2212765, C2212766, EXP 11/30/2026; C2301027, C2301063, C2301187, C2301188, C2301247, EXP 12/31/2026; C2301356, C2301388, C2301494, C2301478, C2301617, EXP 1/31/2027; C2303381, C2303432, C2303565, C2303630, C2303643, C2303710, EXP 2/28/2027; C2303879, C2303806, C2303895, C2303963, C2304263, C2304264, C2304130, C2304163, C2304427, EXP 3/31/2027	Failing to meet impurity and degradation standards.
9/4/2024	Class 2	Indomethacin Extended-Release Capsules 75 Mg	Glenmark Pharmaceuticals Inc., USA	68462-0325-60, 68462-0325-90	17240105, EXP 12/31/2025	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 1	Freestyle Libre 3 Sensor	https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/abbott-issues-voluntary-medical-device-correction-small-number-freestyle-librer-3-sensors-us
Class 2	Testosterone Gel 1.62%	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209493
Class 2	Timolol Maleate 0.5% Solution	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209586
Class 2	Cefixime Suspension 100 Mg/5ml	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209706
Class 2	Ibuprofen 400 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209462
Class 2	Ibuprofen 600 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209459
Class 2	Ibuprofen 800 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209452
Class 2	Indomethacin Extended-Release Capsules 75 Mg	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209413